These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38110609)

  • 1. TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.
    Yang SM; Ghoshal A; Hubbard JM; Gackière F; Teyssié R; Neale SA; Hopkins SC; Koblan KS; Bristow LJ; Dedic N
    Neuropsychopharmacology; 2024 Jun; 49(7):1091-1103. PubMed ID: 38110609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.
    Alvarsson A; Zhang X; Stan TL; Schintu N; Kadkhodaei B; Millan MJ; Perlmann T; Svenningsson P
    J Neurosci; 2015 Oct; 35(41):14057-69. PubMed ID: 26468205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.
    Dedic N; Dworak H; Zeni C; Rutigliano G; Howes OD
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.
    Heffernan MLR; Herman LW; Brown S; Jones PG; Shao L; Hewitt MC; Campbell JE; Dedic N; Hopkins SC; Koblan KS; Xie L
    ACS Med Chem Lett; 2022 Jan; 13(1):92-98. PubMed ID: 35047111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding.
    Dedic N; Wang L; Hajos-Korcsok E; Hecksher-Sørensen J; Roostalu U; Vickers SP; Wu S; Anacker C; Synan C; Jones PG; Milanovic S; Hopkins SC; Bristow LJ; Koblan KS
    Mol Metab; 2024 Feb; 80():101883. PubMed ID: 38237896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data.
    Siafis S; Chiocchia V; Macleod MR; Austin C; Homiar A; Tinsdeall F; Friedrich C; Ramage FJ; Kennett J; Nomura N; Maksym O; Rutigliano G; Vano LJ; McCutcheon RA; Gilbert D; Ostinelli EG; Stansfield C; Dehdarirad H; Juma DO; Wright S; Simple O; Elugbadebo O; Tonia T; Mantas I; Howes OD; Furukawa TA; Milligan L; Moreno C; Elliott JH; Hastings J; Thomas J; Michie S; Sena ES; Seedat S; Egger M; Potts J; Cipriani A; Salanti G; Leucht S
    Wellcome Open Res; 2024; 9():182. PubMed ID: 39036710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamatergic Innervation onto Striatal Neurons Potentiates GABAergic Synaptic Output.
    Paraskevopoulou F; Herman MA; Rosenmund C
    J Neurosci; 2019 Jun; 39(23):4448-4460. PubMed ID: 30936241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
    Milanović S; Dedic N; Lew R; Burton D; Koblan KS; Camilleri M; Hopkins SC
    Diabetes Obes Metab; 2024 Jun; 26(6):2466-2475. PubMed ID: 38533552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics.
    Ågren R; Betari N; Saarinen M; Zeberg H; Svenningsson P; Sahlholm K
    Int J Neuropsychopharmacol; 2023 Sep; 26(9):599-606. PubMed ID: 37549917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity.
    Revel FG; Moreau JL; Gainetdinov RR; Bradaia A; Sotnikova TD; Mory R; Durkin S; Zbinden KG; Norcross R; Meyer CA; Metzler V; Chaboz S; Ozmen L; Trube G; Pouzet B; Bettler B; Caron MG; Wettstein JG; Hoener MC
    Proc Natl Acad Sci U S A; 2011 May; 108(20):8485-90. PubMed ID: 21525407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postsynaptic D2 dopamine receptor supersensitivity in the striatum of mice lacking TAAR1.
    Espinoza S; Ghisi V; Emanuele M; Leo D; Sukhanov I; Sotnikova TD; Chieregatti E; Gainetdinov RR
    Neuropharmacology; 2015 Jun; 93():308-13. PubMed ID: 25721394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats.
    Synan C; Bowen C; Heal DJ; Froger-Colléaux C; Beardsley PM; Dedic N; Hopkins SC; Campbell U; Koblan KS
    Drug Alcohol Depend; 2022 Feb; 231():109261. PubMed ID: 35033729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group III metabotropic glutamate receptors maintain tonic inhibition of excitatory synaptic input to hypocretin/orexin neurons.
    Acuna-Goycolea C; Li Y; Van Den Pol AN
    J Neurosci; 2004 Mar; 24(12):3013-22. PubMed ID: 15044540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons.
    Huang CC; Lo SW; Hsu KS
    J Physiol; 2001 May; 532(Pt 3):731-48. PubMed ID: 11313442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
    Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
    Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: role of D2 dopamine autoreceptors.
    Leo D; Mus L; Espinoza S; Hoener MC; Sotnikova TD; Gainetdinov RR
    Neuropharmacology; 2014 Jun; 81():283-91. PubMed ID: 24565640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum.
    Gerdeman G; Lovinger DM
    J Neurophysiol; 2001 Jan; 85(1):468-71. PubMed ID: 11152748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.
    Achtyes ED; Hopkins SC; Dedic N; Dworak H; Zeni C; Koblan K
    Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1543-1556. PubMed ID: 37165101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substance P selectively modulates GABA(A) receptor-mediated synaptic transmission in striatal cholinergic interneurons.
    Govindaiah G; Wang Y; Cox CL
    Neuropharmacology; 2010 Feb; 58(2):413-22. PubMed ID: 19786036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAAR1 Modulates Cortical Glutamate NMDA Receptor Function.
    Espinoza S; Lignani G; Caffino L; Maggi S; Sukhanov I; Leo D; Mus L; Emanuele M; Ronzitti G; Harmeier A; Medrihan L; Sotnikova TD; Chieregatti E; Hoener MC; Benfenati F; Tucci V; Fumagalli F; Gainetdinov RR
    Neuropsychopharmacology; 2015 Aug; 40(9):2217-27. PubMed ID: 25749299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.